SpringerLink
Log in

Repaglinide a sweeter option than nateglinide in T2DM

  • Clinical study
  • Published:
Inpharma Weekly

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Repaglinide a sweeter option than nateglinide in T2DM. Inpharma Wkly. 1547, 4 (2006). https://doi.org/10.2165/00128413-200615470-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-200615470-00007

Keywords

Search

Navigation